Cubist Systematic Strategies’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Cubist Systematic Strategies’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-63,931	Closed	-$1.21M	–	4628
2023 Q1	$1.21M	Buy	63,931 +19,105	+43%	+$444K	0.01%	2036
2022 Q4	$1.1M	Sell	44,826 -31,999	-42%	-$941K	0.01%	2355
2022 Q3	$1.38M	Buy	76,825 +16,429	+27%	+$296K	0.01%	2349
2022 Q2	$685K	Buy	60,396 +45,896	+317%	+$675K	﹤0.01%	2793
2022 Q1	$323K	Buy	14,500 +4,200	+41%	+$107K	﹤0.01%	2800
2021 Q4	$450K	Buy	+10,300	New	+$412K	﹤0.01%	2523

Other funds holding INBX

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Cubist Systematic Strategies's INBX Position: Q2 2023 in Review

Cubist Systematic Strategies sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2023, closing a stake of 63,931 shares — an estimated $1.21M sold.

Cubist Systematic Strategies first reported a position in INBX in Q4 2021 and held it in 6 quarters. The position peaked at $1.38M in Q3 2022. 107 funds tracked by Wall St. Rank hold INBX as of Q2 2023.

Cubist Systematic Strategies reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Cubist Systematic Strategies sold 63,931 Inhibrx, Inc. Common Stock shares in Q2 2023, an estimated $1.21M.
Cubist Systematic Strategies first reported a position in Inhibrx, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Cubist Systematic Strategies's Inhibrx, Inc. Common Stock position peaked at $1.38M in Q3 2022.
107 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2023.

Based on Cubist Systematic Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.